Moderna, the creators of one of the COVID-19 vaccines, announced that it will work to develop three new mRNA vaccine candidates in 2021 for HIV, seasonal flu, and the Nipah virus.
It has been speculated that mRNA vaccine candidates could have high potential due to the added flexibility of mRNA technology. The technology is different from previous vaccines because it triggers the human body to create proteins that can trigger a defence response from the body. The new mRNA vaccines also do not rely on using parts of an active or dormant virus similar to previous vaccines.
Moderna’s HIV vaccine candidate is being developed in collaboration with the AIDS Vaccine Initiative and also the Bill and Melinda Gates Foundation, and it is scheduled to enter Phase 1 trial before the end of the year.
Vaccine Development Announcements
Moderna Announced Three New Potential mRNA Vaccines
Trend Themes
1. Mrna Vaccine Development - The success of Moderna's COVID-19 vaccine has prompted the development of new mRNA vaccines for HIV, seasonal flu, and Nipah virus, signaling an increased interest in mRNA vaccine technology.
2. Collaborative Vaccine Development - Collaborations between private pharmaceutical companies and public health organizations, such as the Bill and Melinda Gates Foundation, are facilitating vaccine development for diseases that previously lacked attention.
3. Technology-driven Vaccine Development - The use of innovative technology, such as mRNA, is spearheading vaccine development and changing the traditional methods of vaccine research and development.
Industry Implications
1. Pharmaceutical Industry - The pharmaceutical industry is experiencing a shift towards creating vaccines that are based on innovative technology, such as mRNA, which could lead to a competitive advantage for those companies that invest in research and development of such vaccines.
2. Public Health Industry - Increased collaboration between public health organizations and private pharmaceutical companies highlights the importance of prioritizing vaccine development for both infectious and chronic diseases.
3. Technology Industry - The use of innovative technology, such as mRNA, is creating new opportunities for the technology industry to collaborate with the pharmaceutical industry in the development of new vaccine candidates.